Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Healing Diabetic Foot Ulcers with Semaglutide
2025-524738-24-00Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide in diabetic foot ulcer (DFU) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Time to wound closure. Planned start Mar 2026; status: authorised.
02
Drugs
03
Conditions
diabetic foot ulcer (DFU)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-524738-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524738-24-00.